Trial Profile
A pilot phase II open-label study of oglufanide disodium in patients with chronic hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Oglufanide (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Implicit Bioscience
- 27 Jan 2009 Identified and integrated new information source (Australian Clinical Trials Registry record).
- 27 Jan 2009 Status changed from recruiting to completed, according to the Australian New Zealand Clinical Trials Registry.
- 06 Jan 2009 New trial record.